报价延迟最少15分钟:2026/04/25 14:34 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.61 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.30/-2.62
|
|
企业价值
286.89M
|
| 资产负债 |
|
每股账面净值
5.49
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds. |
